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Abstract We have cloned an orphan G protein-coupled receptor 
from a human pituitary cDNA library using a probe generated by 
PCR. The cDNA, designated 119, encodes a protein of 613 amino 
acids that is 45% identical at the amino acid level to the recently 
cloned human Mell~ and Mellb melatonin receptors. Structural 
analyses of the encoded protein and its gene, along with 
phylogenetic analysis, further show that H9 is closely related 
to the G protein-coupled melatonin receptor family. Unusual 
features of the protein encoded by H9 include a lack of N-linked 
glycosylation sites and a carboxyl tail >300 amino acids long. 
H9 transiently expressed in COS-1 cells did not bind 
[12~I]melatonin or [3H]melatonin. H9 mRNA is expressed in 
hypothalamus and pituitary, suggesting that the encoded receptor 
and its natural ligand are involved in neuroendocrine function. 
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1. Introduction 
Melatonin, the principal hormone of the pineal gland, in- 
fluences the timing of mammalian circadian rhythms and reg- 
ulates the reproductive alterations that occur in response to 
changes in day length in seasonally breeding mammals [1]. 
Melatonin elicits these responses through pharmacologically 
specific, guanine nucleotide binding protein (G protein)- 
coupled receptors. 
Recently, a family of G protein-coupled melatonin recep- 
tors have been cloned from Xenopus laevis, chickens and 
mammals [2-5]. These recombinant receptors exhibit similar 
affinity and pharmacological characteristics to each other 
and to endogenous receptors, as defined with the melatonin 
agonist 2-[l~5I]iodomelatonin ([125I]Mel). Two mammalian 
melatonin receptor subtypes have been identified by molecular 
cloning studies. The mammalian Mella melatonin receptor is 
expressed in the hypothalamic suprachiasmatic nuclei (SCN) 
and hypophyseal pars tuberalis, presumed sites of the circa- 
dian and some of the reproductive actions of melatonin, re- 
spectively [3]. The mammalian Mellb melatonin receptor is 
expressed in retina and brain and may mediate the reported 
effects of melatonin on retinal physiology in mammals [4]. A 
third receptor subtype, the Mellc melatonin receptor, has been 
cloned from zebrafish, Xenopus and chickens, but not from 
mammals [5]. 
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We now report the cloning and characterization of H9, a 
cDNA which encodes a newly described G protein-coupled 
receptor. Structurally, H9 is closely related to the cloned 
high-affinity melatonin receptor family, but expression studies 
show that it does not bind either [125I]Mel or [3H]melatonin. 
H9 mRNA is expressed in pituitary and hypothalamus. This 
pattern of expression suggests that the receptor encoded by 
H9 may have a role in human neuroendocrine function. 
2. Materials and methods 
2.1. PCR 
For PCR with degenerate primers, genomic DNA was subjected to 
30 cycles of amplification with 200 nM (final concentration) each of 
two oligonucleotide primers. Each reaction cycle consisted of incuba- 
tions at 94°C for 45 s, 45°C for 2 min and 72°C for 2 min, with 
AmpliTaq DNA polymerase (Perkin-Elmer Cetus). For PCR with 
specific primers, genomic DNA or first-strand cDNA was subjected 
to 25-35 cycles of amplification using incubations at 94°C for 45 s, 
60°C for 45 s and 72°C for 2 or 3 min. Amplified DNA was separated 
on an agarose gel and paper-eluted as previously described [3]. The 
DNA was then subcloned into pCRII using a TA cloning kit (Invi- 
trogen), or digested with restriction enzymes and subcloned into 
pBluescriptlI (Stratagene). 
2.2. Library screening 
Human pituitary and brain cDNA libraries in lambda gtl0 and a 
human genomic library in EMBL-3 SP6/T7 (all from Clontech) were 
plated and transferred to Colony Plaque Screen filters (New England 
Nuclear). The filters were screened under conditions of high strin- 
gency, as previously described [3]. Lambda phage that hybridized to 
the probe were plaque-purified. 
2.3. Rapid amplification of cDNA ends (RACE) 
5'-RACE was performed using the 5'-AmpliFINDER RACE Kit 
(Clontech). First strand cDNA was generated by reverse transcription 
using primer 5'-GGGTAGCTTACAGCCAATACAGCCATA-3' 
based on sequence in the amino terminus of H9. The AmpliFINDER 
anchor was ligated to the cDNA ends using T4 RNA ligase. The 
cDNA was then amplified using an anchor primer (complementary 
to the ampliFINDER anchor) and primer 5'-ATGTTGCTCCTGGG- 
GATCGTTAAGA-3' based on sequence nested just upstream of the 
primer used for reverse transcription. The amplified cDNA was sepa- 
rated on an agarose gel. A specific band at ca. 180 bp was paper 
eluted, subcloned into pCRII, and sequenced. 
2.4. Phylogenetic analysis 
Melatonin receptors, H9 and the rat p, opioid receptor (outgroup) 
were aligned using CLUSTAL W [6]. The alignments were adjusted 
manually, and the regions corresponding to transmembrane s gments 
4-7, as defined by Baldwin [7], were utilized to generate a PAUP data 
matrix [8]. A branch and bound search was performed. The most 
parsimonious tree was found with a tree length of 765. Using 
PAUP, 1000 replicates of bootstrap analysis were performed. A neigh- 
bor-joining tree was calculated using CLUSTAL W and analyzed 
using the bootstrap rocedure [6]. The neighbor-joining tree and the 
maximum parsimony trees do not differ, although the bootstrap val- 
ues do differ. 
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2.5. Binding studies 
COS-1 cells were grown as monolayers in Dulbecco's modified Ea- 
gle's medium (DMEM) supplemented with 10% fetal calf serum, pe- 
nicillin (50 U/ml), and streptomycin (50 lag/ml), in 5% CO2 at 37 C. 
For ligand binding studies, H9 in pcDNA3 was introduced into 
COS-1 cells using the DEAE-dextran method [9]. Three days after 
transfection, medium was removed, and crude membranes were pre- 
pared as described [4]. Binding assays were performed in duplicate in 
a final volume of 200 gl, at 37°C for 60 min or 0°C for 30 min. 
Nonspecific binding was defined using 1000-fold excess of unlabeled 
ligand. Protein measurements were performed by the method of Brad- 
ford [10]. 
2.6. Northern analysis 
Poly(A) + RNA was obtained from human pituitary and hypotha- 
lamus as previously described. The RNA was separated by electro- 
phoresis through a 1% agarose-formaldehyde gel, blotted onto Gene- 
Screen (New England Nuclear), and hybridized with random prime 
labeled probe. Hybridization occurred in 50% formamide, 1M NaC1, 
1% SDS, 10% dextran sulfate, and 100 gg/ml salmon denatured sal- 
mon sperm at 42°C overnight. Final washing was for 1 h at 65°C in 
2 × SSC, 1% SDS. Blots were exposed at -80°C to X-ray film with an 
intensifying screen. Northern blots of human tissues (Human 1 and 
Human II) were also purchased from Clontech and hybridized and 
washed as recommended by the manufacturer. 
2. 7. In situ hybridization 
35S-labeled antisense cRNA probes were generated by digestion of 
pCRII containing a PCR-generated fragment of exon 2 with an ap- 
propriate restriction endonuclease, followed by in vitro transcription 
with T7 RNA polymerase (Ambion) in the presence of [35S]a-thio- 
UTP (New England Nuclear, Boston MA; 110(~1200 Ci/mmol) as 
previously described [11]. As a control, sense cRNA probes were 
generated from the plasmid and processed along with the antisense 
probes. In each case, sense probes applied to sections produced a low, 
homogeneous level of background hybridization. 
In situ hybridization was performed as previously described [11]. 
Film autoradiograms were generated by apposing slides to Kodak SB- 
5 X-ray film (Eastman Kodak, Rochester NY) for 18 days. 
2.8. DNA sequencing 
Nucleotide sequences were analyzed by the dideoxynucleotide chain 
termination method of Sanger et al. [12], using Sequenase (United 
States Biochemical). Sequencing template was double-stranded plas- 
mid. Primers were synthetic oligonucleotides that were either vector 
specific or derived from sequence information. 
2.9. Drugs 
[125I]Mel was purchased from New England Nuclear. All drugs used 
in binding studies were purchased from Sigma, Research Biochemicals 
or synthesized locally. All other chemicals were purchased from Sig- 
ma. 
3. Results 
3.1. Isolation o f  a melatonin-related receptor clone 
To clone melatonin receptor subtypes, we used PCR ampli- 
fication of human genomic DNA with degenerate oligonucleo- 
tide primers based on conserved amino acid residues in the 
third and sixth transmembrane domains of the cloned mela- 
tonin receptors. A novel cDNA fragment (364 bp) was found 
by sequence analysis to be 40% identical at the amino acid 
level with either the human Melh  or Mellb melatonin recep- 
tors. This PCR fragment was random prime labeled and used 
to probe human pituitary and brain cDNA libraries at high 
stringency. Positively hybridizing clones were found only with 
the pituitary library. Restriction endonuclease mapping and 
sequence analysis of several positive phage clones identified 
three overlapping clones that collectively contain an open 
reading frame encoding a protein of 613 AA (estimated 
mol. wt. of 66 923). The flanking sequence of the first methio- 
nine in this reading flame displays a Kozak consensus e- 
quence [13] for the initiation of translation. The three over- 
lapping clones were digested with restriction endonucleases 
and then ligated together to produce clone H9 (Fig. 1). 
3.2. Receptor structure 
Hydropathy analysis of the predicted amino acid sequence 
of H9 using the method of Kyte and Doolittle [14] revealed 
the presence of seven hydrophobic segments and a hydrophilic 
carboxyl tail (data not shown). H9 appears to be closely re- 
lated to a newly described melatonin receptor group that is 
distinct from the other receptor groups (e.g. biogenic amine, 
neuropeptide, and photopigment receptors) that comprise the 
prototypic G protein-coupled receptor superfamily [2-5]. At 
the amino acid level, H9 shows highest identity with the re- 
cently cloned melatonin receptor family and is 45% identical 
overall to the human Mell~ and Mellb receptors. The identity 
increases to 55% when only the transmembrane domains are 
compared. Unique features of the melatonin receptor group 
which are also found for H9 include an NRY sequence just 
downstream from the third transmembrane domain (rather 
than DRY)  and a NAXXY sequence in transmembrane 7 
(rather than NPXXY) (Fig. 1, lower). In addition, H9 and 
the human melatonin receptors all have a CYICHS sequence 
immediately downstream from NRY in the third cytoplasmic 
loop which is a consensus ite for cytochrome c family heme 
binding [15]. The functional significance of this sequence is 
not yet known. 
Distinguishing features of H9 include no consensus ites for 
N-linked glycosylation in either the amino terminus or extra- 
cellular loops (Fig. 1). Also, the carboxyl tail of H9 is over 
300 amino acids long. The carboxyl tail is proline-rich (37 
residues) and contains a consensus equence for the catalytic 
site of a serine protease (boxed). The carboxyl tail has 41 
serine and 18 threonine residues that may function as phos- 
phorylation sites. 
3.3. Gene structure 
The major transcription start site for H9 was determined 
using 5 ' -RACE (see Section 2). Sequence analysis of 5 ' -RACE 
clones showed that they are all identical, with the cap site 138 
bp upstream of the translation start codon. In the 5' untrans- 
lated region, the cDNA sequence matched the sequence or 
genomic clones, indicating that introns are not present in 
this region. Restriction endonuclease mapping and PCR ana- 
lysis of genomic clones showed that the H9 gene is comprised 
of at least 2 exons, separated by an intron that is 3.0 kb in 
length (Fig. 2A). The intron has consensus 5' -GT-AG-3'  se- 
quence for splicing, and the splice sites occur at exactly the 
same location in the coding region as those described for both 
the human Mella and Mellb receptor genes (Fig. 2B). Exon 1 
encodes the entire 5' untranslated region and the coding re- 
gion through the first cytoplasmic loop. Exon 2 encodes the 
rest of the coding region. It may also encode the 3' untrans- 
lated region, but this remains to be determined. Southern 
analysis of human genomic DNA digested with six different 
restriction endonucleases was performed using a PCR frag- 
ment of the second exon of H9 as a hybridization probe. 
Under high stringency conditions, we observed single-band 
patterns, suggesting that H9 is a single copy gene (data not 
shown). 
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H9 •G•TLAV•T•YG••GCKL•QPEY••AL• IFMF.•AMV•T•wDL•GNSM••LA•T•NKKLRNSGN•FwSLSVAD•L•A•YPYPL•LHAMS•GGWDL 96 
95 Human la MQGNGSALPNASQPVLRGDG~. . .RPSwLASALACvL~FT IwDILGNLLVIL~vYRNKKL~NAGNIFvv~LAvADLVVAIYPYPLVLM~IFNNGWNL 108 
Human ib MSENGSFANCCEAGGWAvRPGWSGAGSAR•SRTPR••WvAPAL•AvL IVTTAVDwGNLLv•LSvLRNRKLRNAGNLFLvSLALADLwAFYPYPL ILVA IFYDGWAL 
Consensus . . . . . . . . . . . . . . . . . . . . . . . .  P . . . . . . . . . . . .  T - -VD- -GN- -V IL -V- -N-KLRN-GN-F-VSL- -AD- -VA-YPYPL-L  . . . . .  GW-L 
I I I  IV  V 
H9 SQLQCQMVGFITGLSwGSIFNIvA IA INRYCYICHSLQYERIFSVRNTCIYLV ITWIMTVLAVLPNMYIGT IEYDPRTYTCIFNYLNN•VFTVT IVCIHFVL•LL IVGFC 207 
Human la GYLHCQVSGFLMGLSVIGSIFNITGIAINRYCYICHSLKYDKLYSSKNSLCYVLLIWLLTLAAVLPNLRAGTLQYD•RIYSCTFAQSVSSAYTIAVa/VFHFLVPMI IV IFC 206 
Human Ib GEEHCKASAFVMGLSVIGSvFNITA IA INRYCYICHSMAYHRIYRRWHTPL• ICL IWLLTVVALLPNFFVGSLEYDPRIYSCTF IQTASTQYTAAVVVIHFLLP IAwSFC 219 
Consensus .... C .... F - -GLSV-GS-FNI - - IA INRYCYICHS-  Y . . . . . . . . . . . . . . .  W- -T- -A-LPN- - -G- - -YDPRIY-C-F  . . . . . . . .  T - - -V- -HF- -P- - -V-FC 
V I  V I I  
H9 YVRIWTKVLAARDPAGQNPDNQL. .AEVRNFLTMFVIFLLFAVCWC•INVLTVLVAVS•KEMAGKI•NWL•LAAYFIA•FNSCLNAVIYGLLNENFRREYWTIFHAMRHPI  316 
317 Human la YLR IWILVLQVRQRVKPDRKPKLKPQDFRNFVTMFwFVLFAICWAPLNF IGLAVASDPASMVPRI•EWLFVASYYMAYFNSCLNAI IYGLLNQNFRKEYRRI IVSL•TAR 330 
Human ib YLR IWVLVLQARRK AKPESRLCLKPSDLRSFLTMFVVFVIFAIcWAPLNCIGLAVAINPQEMAPQIPEGLFVTSYLLAYFNSCLNAIVYGLLNQNFRREYKRILLALWNP• 
Consensus Y-RIW -VLQ-R . . . . . . . . .  L ..... R-F-TMFV FV-FA CW-PLN ..... VA- -P- -M-- - IP - -L - - -  y - -AYFNSCLNA--YGLLNQNFR-EY- - I  . . . . . . .  
H9 IFF•G•ISDIREMQEARTLARARAHARDQA•EQDRAHA•PAvEETPMNV•NVPLPGDAAAGHPDRASGH•KPHSRSSSAYRKSASTHHKSVFSHSKAASGHLKPVSGHSKP 427 
Human la VFFVDSSNDVADRVKWKPSPLMTNNNVVKVDSV 350 
Human ib HCIQDASKGSHAEGLQSPAPPI IGVQHQADAL 362 
Consensus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
H9 ASGHPKSATV•PKPASVHFKGDSvHFKGDSVHFKPDSVHFKPASSNPKPITGHHVSAGSHSKSAFSAATSHPKPIKPATSHAEPTTADYPKPATTSHPKPAAADNPELSAS 538 
H9 HCPE IPA IAHPVSDDSDLPESASSPAAGPTKPAASQLESDTIADLPDPTVVTTSTNDYHDV~DVEDDPDEMAV 613 
Fig. 1. Structure of the H9 protein. (Upper) Predicted membrane topology of the H9 protein. A consensus sequence for the active site of a ser- 
ine protease is boxed. (Lower) Comparison of the deduced amino acid sequence of H9 (GenBank accession no. U52219) with the human Mell~ 
melatonin receptor (U14108) and the human Mellb melatonin receptor (U25341). To maximize similarities, gaps (dots) have been introduced 
into the three sequences. The seven presumed transmembrane domains (I-VII) are overlined. Consensus sites for asparagine-linked glycosylation 
are underlined. 
3.4. Evolutionary relationship between H9 and melatonin 
receptors 
We generated an alignment of the regions of H9 and mel- 
atonin receptors from transmembrane segments 4-7, with the 
rat ~ opioid receptor serving as an outgroup. This alignment 
was used to calculate the most parsimonious phylogenetic tree 
using the program PAUP [8]. This tree showed that H9 is 
closely related to the three melatonin receptor subtypes (Fig. 
3). A very similar tree was obtained using the neighbor-join 
method [16]. Bootstrap analyses of the tree and the data set 
showed that the assignment of H9 as a new member of the 
melatonin receptor cluster is strongly supported. 
3.5. Ligand binding studies 
To determine whether H9 encodes a melatonin receptor, 
binding and pharmacological properties were examined by 
transiently expressing H9 in COS-1 cells. H9 did not specifi- 
cally bind 10 nM [125I]Mel, [aH]melatonin, [aH]serotonin, 
[3H]carboxamidotryptamine maleate, [ZH]N-acetylserotonin, 
[ZH]prazosin or [aH]tryptamine at 37°C. It also did not specif- 
ically bind 0.2 nM [125I]Mel at 0°C. Parallel experiments (at 
37°C) showed that COS-I cells transfected with either the 
human Mella or Mellb receptor cDNAs bound [nSI]Mel 
with high affinity, as previously described [3,4]. 
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3.6. Distribution of H9 mRNA 
Northern blot analysis of RNA from human pituitary 
probed with a cDNA fragment from exon 2 revealed a major 
hybridizing transcript at 6.0 kb and a minor one at 9.5 kb 
(Fig. 4). A weak hybridization signal at 6.0 kb was also ob- 
served in hypothalamus. No hybridization signal was appar- 
ent in whole brain, spleen, thymus, prostate, testis, ovary, 
small intestine, colon, peripheral blood leukocytes, heart, pla- 
cental, lung, liver skeletal muscle kidney and pancreas (data 
not shown). 
The anatomical pattern of expression of H9 mRNA was 
assessed by in situ hybridization (Fig. 4). Coronal sections 
(15 pm) from three subjects were examined at ca. 200 urn 
intervals from the optic chiasm through the tuberal region. 
A specific hybridization signal was apparent in the mediobasal 
hypothalamus of one subject, in a region including the ven- 
tromedial and arcuate nuclei of the hypothalamus. The region 
of the paraventricular nucleus of the hypothalamus also con- 
tained specific hybridization in this subject. Sections from the 
other two subjects did not include these regions. H9 was also 
expressed in the pituitary gland and infundibular stalk. Within 
the pituitary gland, expression was widespread and heteroge- 
neous. 
Near-adjacent sections from each subject were processed for 
in vitro autoradiography with [1251]Mel (40 pM; non-specific 
binding determined with 1 pM melatonin). In each subject, 
specific [1251]Mel binding was present in the SCN, but was not 
detected in the regions expressing H9 mRNA. 
4. Discussion 
H9 encodes a putative G protein-coupled receptor that is 
closely related to the recently defined melatonin receptor 
group. Structurally, there are remarkable similarities between 
H9 and the cloned melatonin receptors which distinguish 
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Fig. 2. Structure of the H9 gene. A: The upper portion depicts the 
receptor gene with exons illustrated as bars. Translated regions of 
the exons are black, while the 5’ untranslated region is open. Below 
the gene, the receptor cDNA is shown with the coding region de- 
picted as a wide bar; transmembrane domains I-VII are indicated. 
The thin lines depict the untranslated regions. Dashed lines between 
the gene and cDNA show the portions of the gene encoding the 
cDNA. B: Location and consensus sequence of exon-intron splice 
sites are shown. 
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Fig. 3. Phylogenetic analysis of H9 and melatonin receptors. The re- 
gions comprising transmembrane segments 47 were used to calcu- 
late a tree using the maximum parsimony method. The numbers 
above and below the branches are the results of bootstrap analysis 
and are related to a confidence limit for the positions of the 
branches. The rat p opioid receptor sequence provided an outgroup 
for the tree. GenBank accession numbers not previously published 
(see reference 5) are U52220 (26.2) U52221 (sheep H9), and 
U52218 (rat H9). 
protein-coupled receptor superfamily. In addition, the gene 
structure of H9 is very similar to that of the Meli,, Melit, 
and Meli, melatonin receptors. Moreover, phylogenetic ana- 
lysis confirms a close resemblance between H9 and the high- 
affinity melatonin receptors (Fig. 3), suggesting that they all 
evolved from the same ancestral gene. 
H9 has some unusual structural features. First, it lacks N- 
linked glycosylation sites in the amino terminus and extracel- 
lular loops. Another G protein-coupled receptor, the r&u- 
adrenergic receptor, has been reported which does not contain 
N-linked glycosylation sites [ 17- 191. This lack of glycosylation 
sites for the recombinant adrenergic receptors of rats, humans 
and mice is consistent with biochemical analysis of purified 
endogenous protein which does not have any associated oli- 
gosaccharide moieties [20]. Importantly, the endogenous and 
recombinant asu-adrenergic receptors exhibit high-affinity li- 
gand binding characteristics. Thus, it seems unlikely that the 
lack of glycosylation sites has significant functional conse- 
quences or contributes to our inability to detect ligand bind- 
ing for H9. 
A second unusual feature of H9 is the length of its carboxyl 
tail. The tail length is longer than that reported for any other 
cloned prototypic G protein-coupled receptor (search of G 
protein-coupled receptor data base). Based on studies with 
other G protein-coupled receptors, the carboxyl tail may be 
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Fig. 4. Distribution of H9 mRNA. (Top) Northern blot analysis. Each lane contained 3 gg of poly(A) + RNA. RNA size markers are indicated. 
Blot was exposed to X-ray film for 3 days. The lower portion of the blot depicts hybridization pattern using an actin probe to verify equal 
loading of lanes (arrow). (Bottom) In situ hybridization. (A,C) Hybridization signal is present in the mediobasal hypothalamus (MBH), infun- 
dibular stalk (IS), and pituitary gland (Pit) of sections hybridized with an antisense cRNA probe. (B,D) Non-specific hybridization of the sense 
control probe to adjacent sections at each level. ON, optic nerve; 3V, third ventricle. The width of each panel represents 1.4 mm actual size. 
involved in receptor coupling to G proteins, tethering the 
receptor to the plasma membrane or phosphorylat ion events 
[21]. The identification of a consensus ite for a serine protease 
in the carboxyl tail of H9 raises the interesting possibility that 
the receptor tail has enzymatic function, which may depend 
on receptor activation and/or phosphorylat ion state. The tail 
224 
may also be a site of proteolysis with cleaved portions of the 
tail serving some intracellular function. 
The natural igand for the receptor encoded by H9 is likely 
a molecule related to melatonin. Our ligand binding studies 
strongly suggest hat H9 does not bind melatonin, although 
we did not prove that the receptor protein is actually ex- 
pressed and intercalated into the plasma membrane of COS- 
1 cells. Consistent with our ligand binding studies is the find- 
ing that H9 mRNA is expressed in structures that do not bind 
[125I]Mel. We have also cloned cDNA fragments from rats 
and sheep that are species homologs of H9 (Fig. 3). In these 
animals, the expression pattern of H9 mRNA by in situ hy- 
bridization also does not match the [a25I]Mel binding pattern 
(unpublished). The expression of H9 mRNA in human hy- 
pothalamus and pituitary suggests that the receptor and its 
ligand are involved in the regulation of neuroendocrine func- 
tion. 
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